Immunofoco
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biopharma focused on innovative antibodies and vaccines for cancer and infections.
OncologyInfectious Diseases
Technology Platform
Integrated antibody discovery and development engine, from phage display libraries through to in-house GMP manufacturing of clinical-grade material.
Opportunities
Its in-house manufacturing provides a cost advantage and strategic control over supply, which is valuable for both therapeutics and vaccines.
Risk Factors
Commercial failure of its lead PD-1 candidate in a crowded market could severely impact revenue projections and funding for other pipeline assets.
Competitive Landscape
Entering a saturated PD-1/L1 market in China while also competing in the strategic vaccine sector against large state-backed firms.